Roszik Jason, Mustachio Lisa Maria, Livingston John A, Groisberg Roman, Carmagnani Pestana Roberto, Subbiah Vivek, Conley Anthony P
Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel). 2021 Oct 19;13(20):5249. doi: 10.3390/cancers13205249.
Soft tissue sarcomas, depending on the subtype and grade, frequently recur and become metastatic after localized treatment. There is now great interest in applying immunotherapy to sarcomas to immuno-profile the different subtypes and immune monitor for prognosis. Our group previously showed that key immunotherapy target genes are present in sarcomas. Here, we extend our findings by demonstrating that sarcomas with a relatively high mutational load are likely to be more sensitive to immunotherapy compared to sarcomas with a lower mutation load. We also show that sarcomas with a higher mutation load are associated with the expression of key immune-related genes. We found that CD8+ T cells are present in sarcoma subtypes and that is highly expressed. These findings further define potential mechanisms behind the immunotherapy response of specific sarcoma subtypes and can be used to develop more optimal treatments in the future.
软组织肉瘤根据亚型和分级的不同,在局部治疗后常出现复发并发生转移。目前,将免疫疗法应用于肉瘤以对不同亚型进行免疫分型并监测免疫预后受到了广泛关注。我们团队之前的研究表明,肉瘤中存在关键的免疫疗法靶基因。在此,我们进一步拓展了研究结果,证明与低突变负荷的肉瘤相比,具有相对高突变负荷的肉瘤可能对免疫疗法更敏感。我们还表明,具有较高突变负荷的肉瘤与关键免疫相关基因的表达有关。我们发现肉瘤亚型中存在CD8 + T细胞且其高表达。这些发现进一步明确了特定肉瘤亚型免疫疗法反应背后的潜在机制,并可用于未来开发更优化的治疗方法。